Teva Pharmaceutical Industries Ltd

TEVA remains in a Stage 4 decline with confirmed lower highs and lower lows under downward‐sloping EMAs. Medium‐term bias is bearish, but price is extreme oversold and trading below the 9/21/50 EMA cluster, making immediate sell entries unattractive. We will defer execution and stalk for a bounce into the EMA resistance zone, offering a higher‐probability setup to trim positions.

• ↑Q1 revenue $4B (+4% YoY; +7% ex-divestments).
• ↑Adjusted EBITDA +7% YoY; non-GAAP EPS +10% YoY.
• ↓Shares trade ~64% above GF Value; weak book-to-price and dividend yield.